Here, we provide evidence for a novel mechanism in which the transcription factor GLI2 acts as a downstream effector of transforming growth factor β1 (TGFβ1) signaling in CAFs to drive therapeutic resistance in PC cells. Here, TGFB1 is linked to pachyonychia congenita.